新型冠状病毒感染中医药临床研究：证据现状、问题与挑战
Clinical research of traditional Chinese medicine for COVID-19: evidence, issues and challenges
- 现代中医临床 2023年30卷第4期 页码：12-16
- 作者机构：
北京中医药大学循证医学中心 北京 100029
- 作者简介：
刘建平，男，博士，教授，博士生导师，E-mail：Liujp@bucm.edu.cn
- 基金信息：国家重点研发计划项目(2018YFE102300)
DOI：10.3969/j.issn.2095-6606.2023.04.003
中图分类号： R-03纸质出版日期：2023-07-30，
收稿日期：2023-04-27，
- 稿件说明：
移动端阅览
刘建平. 新型冠状病毒感染中医药临床研究：证据现状、问题与挑战[J]. 现代中医临床, 2023,30(4):12-16.
LIU Jianping. Clinical research of traditional Chinese medicine for COVID-19: evidence, issues and challenges[J]. Modern Chinese Clinical Medicine, 2023,30(4):12-16.
刘建平. 新型冠状病毒感染中医药临床研究：证据现状、问题与挑战[J]. 现代中医临床, 2023,30(4):12-16. DOI： 10.3969/j.issn.2095-6606.2023.04.003.
LIU Jianping. Clinical research of traditional Chinese medicine for COVID-19: evidence, issues and challenges[J]. Modern Chinese Clinical Medicine, 2023,30(4):12-16. DOI： 10.3969/j.issn.2095-6606.2023.04.003.
摘要
在既往新型冠状病毒感染(简称“新冠感染”)大流行的3年中，中医药从疫情初始便介入了对新冠感染的防控和临床救治，取得令人瞩目的成就。本文总结了中医药预防和治疗新冠感染及其后遗症的临床科研证据的现状及存在问题，并提出紧急公共卫生流行事件下中医药研究的策略，力求为今后疫病的中医药防治提供参考。已有证据显示，中医药有助于预防新冠感染、降低密接者的转阳率、降低新冠感染患者的病毒载量；有助于改善新冠感染症状、缓解炎症、降低重症率、缩短转阴时间；有助于改善长新冠患者的消化道症状和呼吸道症状，提升肺功能。虽然中医药防治新冠感染的研究与成果发表不断增多，但其中包含大量的横断面研究、队列研究、病例报告等低等级证据类型，仍缺乏多中心、大样本、安慰剂对照、双盲设计的随机对照试验以及进一步的系统评价与Meta分析。
Abstract
In the past three years of the COVID-19 pandemic
traditional Chinese medicine has been involved in the prevention and treatment for the viral disease since the beginning of the outbreak
and has made remarkable achievements. This study summarized the progress and existing problems of clinical research of traditional Chinese medicine for COVID-19
and proposed strategies for future TCM studies in case of public health emergency in relation to communicable diseases
to inform practice and policy. Evidence shows that traditional Chinese medicine has potential benefits in COVID-19 prevention
treatment and recovery
may help to reduce the infection rate of close contacts
reduce the viral load; improve the symptoms
relieve inflammation
reduce the rate of progression into severe cases
and shorten the time for viral clearance; improve gastrointestinal and respiratory symptoms and lung function in patients after COVID-19. Although large number of TCM studies on COVID-19 have been published
most of the evidence is of low quality. Therefore
more multi-center
large-sample
placebo-controlled
double-blind randomized controlled trials and related systematic reviews and meta-analyses are needed in the future.
关键词
新型冠状病毒感染临床研究证据中医药
Keywords
COVID-19clinical research evidencetraditional Chinese medicine
references
LUO H, TANG Q L，SHANG Y X，et al. Can Chinese medicine be used for prevention of Corona virus disease 2019 (COVID-19)? A review of historical classics，research evidence and current prevention programs[J/OL].Chin J Integr Med,2020,26(4):243-250[2023-04-25].https://pubmed.ncbi.nlm.nih.gov/32065348/https://pubmed.ncbi.nlm.nih.gov/32065348/.
LUO H，YANG M，TANG Q L，et al. Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19)：a scoping review[J/OL]. Eur J Integr Med,2021, 41:101251[2023-04-25].https://pubmed.ncbi.nlm.nih.gov/33204368/https://pubmed.ncbi.nlm.nih.gov/33204368/.
阎博华，蒋志伟，曾洁萍，等.藿香正气口服液与金蒿解热颗粒联合使用对社区人群预防性干预COVID-19的大样本前瞻性临床研究[J].中国中药杂志，2020,45(13):2993-3000.
王晓骁，窦莉，邹冲，等.中医药影响新型冠状病毒肺炎密接者转阳率的研究：一项大样本队列研究[J].南京中医药大学学报，2022,38(12):1086-1093.
YANG M，SHANG Y X，TIAN Z Y，et al. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19)：a systematic review[J/OL]. Integr Med Res,2020,9(3):100426[2023-04-25].https://pubmed.ncbi.nlm.nih.gov/32483523/https://pubmed.ncbi.nlm.nih.gov/32483523/.
LIU J，DONG F，ROBINSON N . State-of-the-art evidence of traditional Chinese medicine for treating coronavirus disease 2019[J/OL]. Journal of Traditional Chinese Medical Sciences,2022,9(1):5[2023-04-25].https://kns.cnki.net/kcms2/article/abstract？v＝8xl4CyPd-wX4oObJLcr_YNwWCSEuGnENWyzqrTmiLa8lL1c_u_pnrdcl4O5p0fKpe6dE5uLbREj-So-1mZxWAxqoUZDoksbo94i2XaJA-utz_F1_MtbZAKRTBtc13Roc&uniplatform＝NZKPT&language＝gbhttps://kns.cnki.net/kcms2/article/abstract？v＝8xl4CyPd-wX4oObJLcr_YNwWCSEuGnENWyzqrTmiLa8lL1c_u_pnrdcl4O5p0fKpe6dE5uLbREj-So-1mZxWAxqoUZDoksbo94i2XaJA-utz_F1_MtbZAKRTBtc13Roc&uniplatform＝NZKPT&language＝gb.
WU X，LI W，QIN Z，et al. Traditional Chinese medicine as an adjunctive therapy for mild and common COVID-19: a systematic review and network meta-analysis[J/OL]. Medicine (Baltimore),2021,100(40):e27372[2023-04-25].https://pubmed.ncbi.nlm.nih.gov/34622839/https://pubmed.ncbi.nlm.nih.gov/34622839/.
LIANG S B，FANG M，LIANG C H，et al. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: a rapid systematic review and meta-analysis of randomized controlled trials[J/OL].Complement Ther Med,2021,60:102744[2023-04-25]. https://pubmed.ncbi.nlm.nih.gov/34091029/https://pubmed.ncbi.nlm.nih.gov/34091029/.
LIANG S B，ZHANG Y Y，SHEN C，et al. Chinese herbal medicine used with or without conventional western therapy for COVID-19: an evidence review of clinical studies[J/OL]. Front Pharmacol,2021,11:583450[2023-04-25]. https://pubmed.ncbi.nlm.nih.gov/33716720/https://pubmed.ncbi.nlm.nih.gov/33716720/.
孟家乐，袁思成，王毅军，等.井穴和耳尖放血治疗新型冠状病毒感染无症状及轻症外感风热证咽痛患者回顾性队列研究[J].中国中西医结合杂志，2023,43(4):410-414.
SELVAKUMAR J，HAVDAL L B，DREVVATNE M，et al. Prevalence and characteristics associated with post-COVID-19 condition among nonhospitalized adolescents and young adults[J/OL].JAMA Netw Open,2023,6(3):e235763[2023-04-25]. https://pubmed.ncbi.nlm.nih.gov/36995712/https://pubmed.ncbi.nlm.nih.gov/36995712/.
SALAMANNA F，VERONESI F，MARTINI L，et al. Poste COVID-19 syndrome：the persistent symptoms at the post-viral stage of the disease. A systematic review of the current data[J/OL]. Front Med,2021,8:653516[2023-04-25].https://pubmed.ncbi.nlm.nih.gov/34017846/https://pubmed.ncbi.nlm.nih.gov/34017846/.
AN X，PENG B，HUANG X，et al. Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized，double-blind，placebo-controlled multicenter trial[J/OL]. Chin Med,2022,17(1):42[2023-04-25].https://pubmed.ncbi.nlm.nih.gov/35366928/https://pubmed.ncbi.nlm.nih.gov/35366928/.
聂天旸，陈卫衡，于会勇，等.桔杏君子颗粒治疗新冠感染恢复期患者的作用评价与机制探讨[J/OL].辽宁中医药大学学报,1-20[2023-04-25].http://kns.cnki.net/kcms/detail/21.1543.R.20230221.1831.009.htmlhttp://kns.cnki.net/kcms/detail/21.1543.R.20230221.1831.009.html.
强晓钰，陈哲，季昭臣，等.中医药对新型冠状病毒肺炎(COVID-19)恢复期患者肺功能影响的Meta分析[J].环球中医药，2023,16(2):226-233.
CHAICHANA U，MAN KKC，CHEN A，et al. Definition of post-COVID-19 condition among published research studies[J/OL].JAMA Netw Open,2023,6(4):e235856[2023-04-25].https://pubmed.ncbi.nlm.nih.gov/37017970/https://pubmed.ncbi.nlm.nih.gov/37017970/.
WORLD HEALTH ORGANIZATION. Pandemic influenza preparedness and response—WHO guidance document [EB/OL][2023-04-25].https://www.who. int/influenza/resources/documents/pandemic_ guidance_04_2009/en/https://www.who. int/influenza/resources/documents/pandemic_ guidance_04_2009/en/.
杨鸣，张颖，董斐，等.中医药参与新型冠状病毒肺炎治疗的临床研究策略与方法思考[J]. 中国中西医结合杂志，2020,40(3):283-286.
0
浏览量
193
下载量
0
CSCD
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies